Levi & Korsinsky notifies investors that it has commenced an investigation into Larimar Therapeutics, Inc. (NASDAQ: LRMR) concerning potential violations of the federal securities laws.
Larimar issued a press release on September 29, 2025, announcing data from an ongoing long-term open-label study evaluating daily subcutaneous injections of Nomlabofusp in participants with Friedreich's Ataxia. Although Larimar characterized the data as "positive", the press release disclosed that anaphylaxis or a severe allergic reaction was reported in seven participants. Following this news, Larimar's stock price fell over 33% on September 29, 2025.
If you suffered a loss on your Larimar Therapeutics, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





